OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Editorial Board	462
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	434
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	379
Treatment strategies for leptomeningeal disease in patients with breast cancer	294
Unfolded protein responses: Dynamic machinery in wound healing	289
Editorial Board	252
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	222
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	216
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	209
Adenosine receptor signalling as a driver of pulmonary fibrosis	178
Matrikines in the skin: Origin, effects, and therapeutic potential	169
Treatment approaches for alcohol use disorder with metabolic dysfunction	130
The role of macrophages in asthma-related fibrosis and remodelling	128
Collateral lethality: A unique type of synthetic lethality in cancers	127
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	120
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	115
Inflammation, lipids, and pain in vulvar disease	113
Non-canonical G protein signaling	112
Endothelial dysfunction as a complication of anti-cancer therapy	99
SGLT2 inhibitors: Do they have antiarrhythmic properties?	95
Potential neonatal toxicity of new psychoactive substances	94
Editorial Board	93
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	93
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	90
TAAR1 as an emerging target for the treatment of psychiatric disorders	89

Management of drug-resistant hypertension as a heterogeneous disorder	89
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	87
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	86
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	84
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	83
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	81
Boron in cancer therapeutics: An overview	81
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	81
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	78
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	77
Dysregulation of metabolic pathways in pulmonary fibrosis	77
Review: Sex-related differences in the treatment of cardiac arrhythmia	77
Natural products that alleviate depression: The putative role of autophagy	75
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	75
Bispecific antibodies for the treatment of neuroblastoma	74
Editorial Board	73
Editorial Board	73
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	72
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	72
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	71
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
PGRMC1: An enigmatic heme-binding protein	70
Pharmacological treatment of cardiogenic shock – A state of the art review	70
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	68
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	67
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	66
Stabilizing the neural barrier – A novel approach in pain therapy	66
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	65
Insights into effective protocol structuring: optimizing dosing strategies, experimental design, and statistical approaches	65
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	65
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	63
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	63
Advances in pathogenesis and therapeutic strategies for osteoporosis	63
DNA methylation in cell plasticity and malignant transformation in liver diseases	63
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	63
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	61